This study is designed to determine whether levodopa will lead to an improvement in the
development and tremor in children with Angelman syndrome (AS).
It has been suggested that levodopa, a medication that is usually used to treat Parkinson
disease in adults, may help children with AS in their overall development and reduce the
tremor that some of them have.
If levodopa is found to be beneficial for children with AS, this could lead to a new
treatment for AS.
Funding Source - FDA-OOPD
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Wen-Hann Tan
Collaborators:
Angelman Syndrome Foundation, Inc. Baylor College of Medicine Children's Hospital Medical Center, Cincinnati Greenwood Genetic Center Rady Children's Hospital, San Diego University of California, San Francisco Vanderbilt University Vanderbilt University Medical Center